Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Control Release ; 270: 226-236, 2018 01 28.
Artigo em Inglês | MEDLINE | ID: mdl-29196042

RESUMO

As one of the most devastating forms of trauma, spinal cord injury (SCI) remains a challenging clinical problem. The secondary processes associated with the primary injury, such as overproduction of reactive oxygen species (ROS) and inflammation, lead to concomitant compression of the injured spinal cord and neuronal death. Delivery of copper-zinc superoxide dismutase (SOD1), an efficient ROS scavenger, to the site of injury can mitigate SCI-induced oxidative stress and tissue damage. Towards this goal catalytically active nanoformulations of SOD1 ("nanozymes") are developed as a modality for treatment of SCI. Along with the cross-linked polyion complex of SOD1 with polycation poly(ethylene glycol) (PEG)-polylysine (single-coat (SC) nanozyme), we introduce for the first time the chemically cross-linked multilayer polyion complex in which SOD1 is first incorporated into a polyion complex with polycation, then coated by anionic block copolymer, PEG-polyglutamic acid (double-coat (DC) nanozyme). We developed DC nanozymes with high enzymatic activity and ability to retain and protect SOD1 under physiological conditions. Pharmacokinetic study revealed that DC nanozymes significantly prolonged circulation of active SOD1 in the blood stream compared to free SOD1 or SC nanozymes (half-life was 60 vs 6min). Single intravenous injection of DC nanozymes (5kU of SOD1/kg) improved the recovery of locomotor functions in rats with moderate SCI, along with reduction of swelling, concomitant compression of the spinal cord and formation of post-traumatic cysts. Thus, based on the testing in a rodent model the SOD1 DC nanozymes are promising modality for scavenging ROS, decreasing inflammation and edema, and improving recovery after SCI.


Assuntos
Nanopartículas/administração & dosagem , Traumatismos da Medula Espinal/tratamento farmacológico , Superóxido Dismutase-1/administração & dosagem , Doença Aguda , Animais , Feminino , Locomoção/efeitos dos fármacos , Masculino , Polímeros/administração & dosagem , Polímeros/farmacocinética , Ratos Sprague-Dawley , Ratos Wistar , Traumatismos da Medula Espinal/fisiopatologia , Superóxido Dismutase-1/farmacocinética
2.
J Control Release ; 213: 36-44, 2015 Sep 10.
Artigo em Inglês | MEDLINE | ID: mdl-26093094

RESUMO

Copper/zinc superoxide dismutase (CuZnSOD; SOD1) is widely considered as a potential therapeutic candidate for pathologies involving oxidative stress, but its application has been greatly hindered by delivery issues. In our previous study, nanoformulated SOD1 (cl-nanozyme) was shown to decrease infarct volume and improve sensorimotor functions after a single intravenous (IV) injection in a rat middle cerebral artery occlusion (MCAO) model of ischemia/reperfusion (I/R) injury (stroke). However, it remained unclear how cl-nanozyme was able to deliver SOD1 to the brain and exert therapeutic efficacy. The present study aims to answer this question by exploring micro-distribution pattern of cl-nanozyme in the rat brain after stroke. Immunohistochemistry studies demonstrated cl-nanozyme co-localization with fibrin along damaged arteries and capillaries in the ischemic hemisphere. We further found that cl-nanozyme can be cross-linked into thrombi formed after I/R injury in the brain, and this effect is independent of animal species (rat/mouse) used for modeling I/R injury. This work is also the first report reinforcing therapeutic potential of cl-nanozyme in a well-characterized mouse MCAO model of I/R injury.


Assuntos
Encéfalo/irrigação sanguínea , Infarto da Artéria Cerebral Média/tratamento farmacológico , Substâncias Protetoras/farmacocinética , Substâncias Protetoras/uso terapêutico , Superóxido Dismutase-1/farmacocinética , Superóxido Dismutase-1/uso terapêutico , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Isquemia Encefálica/tratamento farmacológico , Isquemia Encefálica/patologia , Artérias Cerebrais/efeitos dos fármacos , Artérias Cerebrais/patologia , Terapia Enzimática , Infarto da Artéria Cerebral Média/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Substâncias Protetoras/administração & dosagem , Ratos , Ratos Sprague-Dawley , Superóxido Dismutase-1/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA